Bloomberg.com · Reporting
Oct 7, 2026
Vertical + Enterprise · Private company · Growth
Isomorphic Labs
✓ VerifiedIsomorphic Labs matters because it represents one of the strongest attempts to turn frontier AI research into a drug-discovery company with real pharma leverage.
London, UKFounded 2021No public API trackedWeekday review target
Editorial intelligence brief
Editorial focus
Isomorphic Labs continues building AI drug design programs and pharmaceutical partnerships around its AlphaFold-derived research stack.
Focus: AI-first drug discovery built on frontier biology and model-driven design
Latest funding
$2.1B
Series B · source-backed
Tracked funding
$2.1B
Sum of itemized funding events
Latest valuation
Not tracked
No source-backed record
Latest revenue
Not tracked
Growth lifecycle position
Editorially verified updates
What changed
Isomorphic Labs continues building AI drug design programs and pharmaceutical partnerships around its AlphaFold-derived research stack.
External coverage of Isomorphic Labs
Selected by relevance, date and publisher; grouped by story. External reporting is not independently verified by the map. Article dates are publisher timestamps supplied by the discovery feed; quieter profiles may show coverage up to 90 days old.
Last checked Oct 18, 2026.
Isomorphic Labs · Primary source
Sep 29, 2026
Source-backed financial history
Funding and financial history
Funding, valuation, revenue, and debt are kept separate so unlike measurements are never presented as one trend.
Records
1
Sum of recorded funding
$2.1B
Coverage
partial
Partial history: earlier or intervening rounds may be missing. The sum covers only the announcements recorded here, not lifetime funding. Announced commitments may be paid over time; this is not a cash balance. Dates show announcements or first public reports, which can follow the investment itself.
One funding announcement recorded. More dated rounds are needed to show funding over time.
#1
Series B · $2.1B
Running tracked total: $2.1B
#1
Series B · $2.1B
Running tracked total: $2.1B
Sources and details for every recorded funding announcement, newest first.
Series B · $2.1B
$2.1B Series B.
Product surface
Products and model families
Recent models
No standalone model family is structured for this profile.
Products
AI drug design platform
Open weights
No
API access
No
Review target
Weekday
Market position
Lifecycle and strategic signals
Research
Preview
Growth
Deployment
Growth: Public access & scaling
Focus
AI-first drug discovery built on frontier biology and model-driven design
Signals
ScienceBiotechScientific discovery
Taxonomy
Frontier LabsBiotechAI for scienceResearch
Competitive context
Insilico MedicineRecursionGenerate:Biomedicines
Infrastructure & distribution
Where Isomorphic Labs sits in the AI stack
01
Model layer
No standalone model family tracked
02
Access layer
Application or managed product
03
Market layer
Vertical + Enterprise
Public product surface
AI drug design platform
Stack signals
BiotechAI for scienceResearchScienceScientific discovery
This section reflects publicly visible product and access signals. Undisclosed GPU, cloud, training, and data-center contracts are not inferred.
Evidence trail
Sources and corrections
Primary and public sources used to verify the structured company profile.
The Staticbreaker
Get the signal behind the week's AI changes.
The Staticbreaker turns launches, category shifts, and market noise into a concise editorial briefing.